Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 1
2017 1
2018 2
2019 2
2020 3
2021 4
2022 3
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S; MAGNITUDE Principal Investigators. Chi KN, et al. J Clin Oncol. 2023 Jun 20;41(18):3339-3351. doi: 10.1200/JCO.22.01649. Epub 2023 Mar 23. J Clin Oncol. 2023. PMID: 36952634 Free PMC article. Clinical Trial.
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S; TITAN Investigators. Chi KN, et al. N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31. N Engl J Med. 2019. PMID: 31150574 Free article. Clinical Trial.
The Mutographs biorepository: A unique genomic resource to study cancer around the world.
Perdomo S, Abedi-Ardekani B, de Carvalho AC, Ferreiro-Iglesias A, Gaborieau V, Cattiaux T, Renard H, Chopard P, Carreira C, Spanu A, Nikmanesh A, Cardoso Penha RC, Antwi SO, Ashton-Prolla P, Canova C, Chitapanarux T, Cox R, Curado MP, de Oliveira JC, Dzamalala C, Fabianova E, Ferri L, Fitzgerald R, Foretova L, Gallinger S, Goldstein AM, Holcatova I, Huertas A, Janout V, Jarmalaite S, Kaneva R, Kowalski LP, Kulis T, Lagiou P, Lissowska J, Malekzadeh R, Mates D, McCorrmack V, Menya D, Mhatre S, Mmbaga BT, de Moricz A, Nyirády P, Ognjanovic M, Papadopoulou K, Polesel J, Purdue MP, Rascu S, Rebolho Batista LM, Reis RM, Ribeiro Pinto LF, Rodríguez-Urrego PA, Sangkhathat S, Sangrajrang S, Shibata T, Stakhovsky E, Świątkowska B, Vaccaro C, Vasconcelos de Podesta JR, Vasudev NS, Vilensky M, Yeung J, Zaridze D, Zendehdel K, Scelo G, Chanudet E, Wang J, Fitzgerald S, Latimer C, Moody S, Humphreys L, Alexandrov LB, Stratton MR, Brennan P. Perdomo S, et al. Among authors: stakhovsky e. Cell Genom. 2024 Mar 13;4(3):100500. doi: 10.1016/j.xgen.2024.100500. Epub 2024 Feb 6. Cell Genom. 2024. PMID: 38325367 Free PMC article. Review.
Ornithine decarboxylase activity in prostate cancer.
Samoylenko ОА, Stakhovsky EO, Vitruk YV, Shlyakhovenko VO. Samoylenko ОА, et al. Among authors: stakhovsky eo. Exp Oncol. 2021 Mar;43(1):46-51. doi: 10.32471/exp-oncology.2312-8852.vol-43-no-1.16011. Exp Oncol. 2021. PMID: 33785708
Osteonectin (SPARC) prognostic value in prostate cancer.
Chekhun V, Borikun T, Zadvornyi T, Mushii O, Stakhovsky E, Vitruk Y, Lukianova N. Chekhun V, et al. Among authors: stakhovsky e. Pathol Res Pract. 2024 Feb;254:155053. doi: 10.1016/j.prp.2023.155053. Epub 2023 Dec 27. Pathol Res Pract. 2024. PMID: 38199134
Advantages of organ-sparing treatment approaches in metastatic kidney cancer.
Vitruk I, Voylenko O, Stakhovsky O, Kononenko O, Pikul M, Semko S, Hrechko B, Koshel D, Stakhovsky E. Vitruk I, et al. Among authors: stakhovsky e. J Cancer Res Clin Oncol. 2023 Jul;149(7):3131-3137. doi: 10.1007/s00432-022-04216-6. Epub 2022 Jul 23. J Cancer Res Clin Oncol. 2023. PMID: 35870012
NANOG as prognostic factor of prostate cancer course.
Zadvornyi TV, Lukianova NY, Borikun TV, Vitruk YV, Stakhovsky EO, Chekhun VF. Zadvornyi TV, et al. Among authors: stakhovsky eo. Exp Oncol. 2020 Jun;42(2):94-100. doi: 10.32471/exp-oncology.2312-8852.vol-42-no-2.14673. Exp Oncol. 2020. PMID: 32602285
Cytochrome P450 genes expression in human prostate cancer.
Maksymchuk O, Gerashchenko G, Rosohatska I, Kononenko O, Tymoshenko A, Stakhovsky E, Kashuba V. Maksymchuk O, et al. Among authors: stakhovsky e. Mol Genet Metab Rep. 2024 Jan 9;38:101049. doi: 10.1016/j.ymgmr.2024.101049. eCollection 2024 Mar. Mol Genet Metab Rep. 2024. PMID: 38469085 Free PMC article.
EXPRESSION OF miRNA AS PROGNOSTIC MARKERS OF RENAL CELL CARCINOMA COURSE.
Vitruk Y, Borikun T, Rossylna O, Zadvornyi T, Semko S, Voylenko O, Stakhovsky O, Shipko A, Stakhovsky E. Vitruk Y, et al. Among authors: stakhovsky e. Exp Oncol. 2022 Aug;44(2):132-136. doi: 10.32471/exp-oncology.2312-8852.vol-44-no-2.17883. Exp Oncol. 2022. PMID: 35964649
Expression of cancer-associated genes in prostate tumors.
Rosenberg EE, Gerashchenko GV, Hryshchenko NV, Mevs LV, Nekrasov KA, Lytvynenko RA, Vitruk YV, Gryzodub OP, Stakhovsky EA, Kashuba VI. Rosenberg EE, et al. Among authors: stakhovsky ea. Exp Oncol. 2017 Jul;39(2):131-137. Exp Oncol. 2017. PMID: 29483498
25 results